This last cell line, and MCF-7 cells transfected with HER2, were five times more sensitive to the effects of oleuropein aglycone than HER2-negative MCF-7 breast cancer cells, indicating a potential anti-tumor effect of oleuropein aglycone in HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.